VELSIPITY

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Oct 12, 2023

   2 yr 9 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   Oct 12, 2028

   in 2 yr 4 mo

4. Patent 9126932 expires

   Listed method-of-use patent (U-3732) expiration.

   Jul 22, 2029

   in 3 yr 2 mo

5. Patent 8580841 expires

   Listed drug substance patent expiration.

   Mar 05, 2030

   in 3 yr 9 mo

6. Patent 11007175 expires

   Listed method-of-use patent (U-3730) expiration.

   Jan 06, 2036

   in 9 yr 8 mo

7. Patent 12156866 expires

   Listed method-of-use patent (U-4047) expiration.

   Jan 06, 2036

   in 9 yr 8 mo

8. Patent 12377071 expires

   Listed method-of-use patent (U-4255) expiration.

   Jan 06, 2036

   in 9 yr 8 mo

9. Patent 10301262 expires

   Listed drug substance patent expiration.

   Jun 21, 2036

   in 10 yr 2 mo

10. Patent 10676435 expires

    Listed method-of-use patent (U-3731) expiration.

    Jun 21, 2036

    in 10 yr 2 mo

11. Patent 11091435 expires

    Listed drug substance patent expiration.

    Jun 21, 2036

    in 10 yr 2 mo

12. Patent 11884626 expires

    Listed method-of-use patent (U-3731) expiration.

    Jun 21, 2036

    in 10 yr 2 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

• NCENew chemical entity exclusivity (5 years)

  Oct 12, 2028

  in 2 yr 4 mo

Listed patents (9)